AbbVie’s Skyrizi Secures FDA Approval for Ulcerative Colitis, Expands Treatment Portfolio
AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has approved...
Genrix Biopharmaceutical and Chongqing Pharmaceutical Group Form Strategic Partnership to Boost Market Launch
Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a biopharmaceutical company based in China, has entered...
AstraZeneca’s Gracell Biotechnologies to Expand Cell Therapy Manufacturing in China
Gracell Biotechnologies, a China-based cell therapy specialist owned by AstraZeneca (AZ; NASDAQ: AZN), is reportedly...
NMPA Releases 81st Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 81st batch of reference drugs for...
Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion
Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has...
3SBio Secures Long-Term Financing from IFC for Manufacturing and Global Expansion
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, is slated to receive long-term...
Hybribio Ltd Secures NMPA Approval for α-Thalassemia Genotyping Detection Kit
Hybribio Ltd (SHE: 300639), a Guangdong-based provider of nucleic acid molecular diagnostic products, has announced...
Kanghong Pharmaceutical’s Lumitin Approved in Myanmar for Neovascular AMD Treatment
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...
Suzhou Zelgen’s Recombinant Human Thyroid Stimulating Hormone Accepted for NMPA Review
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
Sanofi Partners with Belharra Therapeutics to Tap into Chemoproteomics for Immunology Targets
Sanofi (NASDAQ: SNY; EPA: SAN), a major French pharmaceutical company, has formed a collaboration with...
Clover Biopharmaceuticals’ RSV Vaccine Candidate Shows Promising Results in Elderly
Clover Biopharmaceuticals Ltd. (HKG: 2197), a biopharmaceutical company based in China, has announced positive preliminary...
Day One Biopharmaceuticals Expands Pipeline with MabCare Therapeutics Licensing Deal
Day One Biopharmaceuticals (NASDAQ: DAWN), a California-based biotech company that recently celebrated its first drug...
China Medical System’s Methylthioninium Tablets Get NMPA Green Light for Colonoscopy Use
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received New Drug...
AstraZeneca’s AKT Inhibitor Truqap Misses Primary Endpoints in Phase III TNBC Trial
AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has encountered a setback in the Phase...
MSD’s Capvaxive Vaccine Targets 21 Serotypes of Streptococcus Pneumoniae
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced...
Roche Secures RNA Exon Editing Tech for Neurological Diseases with Ascidian Deal
Roche (SWX: ROG; OTCMKTS: RHHBY), a Swiss pharmaceutical giant, is expanding its footprint in the...
Gansu Province Introduces Measures for Management of Pharmaceutical Personnel
The Gansu Medical Products Administration has issued a set of “Measures for the Management of...
Guangdong Pharmaceutical Association Expands Off-Label Drug Use Catalogue for 2024
The Guangdong Pharmaceutical Association (GDPA) has released the Off-label Drug Use Catalogue for the year...
Envonalkib, Chia Tai Tianqing’s Next-Gen ALK Inhibitor, Wins NMPA Approval for Untreated ALK+ NSCLC
Chia Tai Tianqing’s next-generation ALK inhibitor, envonalkib, has received approval from the National Medical Products...
Ascentage Pharma Presents Positive Clinical Results for Olverembatinib and Lisaftoclax at EHA Meeting
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has presented the results of...